

Under the Aegis of
CANCER RESEARCH
AND STATISTIC
FOUNDATION

Institute of Pulmonology
Medical Research & Development

Sunrise
Oncology
Centre

HYBRID
WEBINAR

CONFERENCE VENUE

Sahara Star Hotel, Mumbai

Nehru Rd, opp. Domestic Airport, Navpada, Vile Parle East,
Vile Parle, Mumbai, Maharashtra 400099

th
S

LUNG CANCER



Year End Review 2021

Conference on

10th

11th

12th

December 2021

REGISTER NOW

<https://webinar365.in/hcimpl-LCYER2021/>

TITLE

PAGE NO.

| | |
|------------------------------|------|
| Organising Committee..... | 3-6 |
| National Faculties List..... | 7-10 |

Important Date To Remember

| | |
|-------------------------|-------|
| 10th December 2021..... | 33-36 |
| 12th December 2021..... | 37-44 |
| 13th December 2021..... | 44-50 |

ORGANIZING COMMITTEE

PATRONS



Dr. Pankaj M Shah

Vice President of Gujarat Cancer Society,
Senior Medical Oncologist,
Zydus Hospital, Ahmedabad

Dr. Ramakant Deshpande

Chief Of Thoracic Surgical Oncology
Executive Chairman -
Asian Cancer Institute, Mumbai



ORGANIZING CHAIRPERSON



Dr. Rajesh Mistry

Director, Oncology
Surgical Oncology, Robotic Surgery, Minimal Access Surgery
Kokilaben Dhirubhai Ambani Hospital, Mumbai

Dr. Prashant Chhajed

Chest physician & Interventional Pulmonologist
Lilavati, Nanavati and Fortis Hiranandani Hospital,
Vashi



Dr. Kumar Prabhash

Prof. & Head- Department of Medical Oncology,
Tata Memorial Hospital, Mumbai

SCIENTIFIC COMMITTEE



Dr. V Kannan

Consultant & Head, Radiation Oncology
P. D. Hinduja Hospital, Mumbai

Dr. Vanita Noronha

Professor and Medical Oncologist,
Tata Memorial Hospital, Mumbai



Dr. Navneet Singh

Additional Professor
Department of Pulmonary Medicine
Postgraduate Institute of Medical Education
and Research (PGIMER), Chandigarh

Dr. Sewanti Limaye

Consultant, Medical Oncology
Kokilaben Dhirubhai Ambani Hospital
and Medical Research Institute, Mumbai



Dr. Vijay Patil

Consultant,
Department of Medical Oncology,
Tata Memorial Hospital, Mumbai

SCIENTIFIC COMMITTEE



Dr. Ashay Karpe

Senior Consultant
Haematologist and Medical Oncologist
S. L. Raheja Hospital, Mahim, Mumbai.

Dr. Nandini Menon

Assistant Professor, Medical Oncology
Tata Memorial Hospital, Mumbai



Dr. Akhil Kapoor

Consultant Medical Oncology
Tata Memorial Hospital
(HBCH & MPMMCC), Varanasi.

Dr. Anil Tibdewal

Assistant Professor,
Radiation Oncology
Tata Memorial Centre, Mumbai



Dr. Prriya Eshpuniyani

Consultant Surgical Oncologist
Speciality Thoracic Surgery
Asian Cancer Institute, Mumbai

NATIONAL FACULTIES

Dr. A K Malhotra
Delhi

Dr. Abhinav Zawar
Aurangabad

Dr. Adesh Palekar
Goa

Dr. Aditya Kanteti
Mumbai

Dr. Aditya Murali
Bangalore

Dr. Adwaita Gore
Mumbai

Dr. Ajay Singh
Mumbai

Dr. Akhil Kapoor
Varanasi

Dr. Amit Aggarwal
Raipur

Dr. Amit Jetani
Rajkot

Dr. Amita Athawale
Mumbai

Dr. Amol Dongre
Nagpur

Dr. Anand Pathak
Nagpur

Dr. Anil Tibdewal
Mumbai

Dr. Anjana Joel
Vellore

Dr. Ankita Ahuja
Mumbai

Dr. Anoop Mantri
Indore

Dr. Anu Rajpurohit
Jaipur

Dr. Anuj Gupta
Varanasi

Dr. Anup Toshniwal
Aurangabad

Dr. Arun Chandrashekhran
Kochi

Dr. Arvind Krishnamurthy
Chennai

Dr. Arvind Kumar
Patna

Dr. Asha Kapadia
Mumbai

Dr. Ashay Karpe
Mumbai

Dr. Ashish Bakshi
Mumbai

Dr. Ashish Joshi
Mumbai

Dr. Ashish Singh
Vellore

Dr. B K Mishra
Varanasi

Dr. B K Smruti
Mumbai

Dr. Bharat Bhosale
Mumbai

Dr. Bharath Rangarajan
Coimbatore

Dr. Bhavesh Poladia
Namakkal

Dr. Bipinesh Sansar
Varanasi

Dr. Boman Dhabhar
Mumbai

Dr. C.T. Satheesh
Bangalore

Dr. Caleb Harris
Shillong

Dr. Chakor Vora
Pune

NATIONAL FACULTIES

Dr. Chetan Deshmukh
Pune

Dr. Chirag Desai
Ahmedabad

Dr. D C Doval
Delhi

Dr. D Raghunath Rao
Vizag

Dr. Darshana Rane
Mumbai

Dr. Davinder Paul
Ludhiana

Dr. Deepak Gupta
Jaipur

Dr. Deepak Shukla
Jaipur

Dr. Devayani Niyogi
Mumbai

Dr. Devendra Pal
Mumbai

Dr. Dilip Vallathol
Vishakhapatnam

Dr. G. Sadashivudu
Hyderabad

Dr. Gagan Saini
Delhi

Dr. Ghanshyam Biswas
Bhubaneswar

Dr. Govind Babu
Bangalore

Dr. Gunjesh Kumar Singh
Muzaffarpur

Dr. Gurvinder Singh
Sangrur

Dr. Hemant Malhotra
Jaipur

Dr. Hollis Dsouza
Mumbai

Dr. Itesh Khatwani
Ahmedabad

Dr. Jacob George
Goa

Dr. Jatin Sarin
Chandigarh

Dr. Jayant Gawande
Pune

Dr. Jyotsna Joshi
Mumbai

Dr. K Sambasivaiah
Varanasi

Dr. K. Pavithran
Kochi

Dr. Kaushal Patel
Surat

Dr. Kaustav Talapatra
Mumbai

Dr. Kinjal Jani
Ahmedabad

Dr. Kishore Kota
Varanasi

Dr. Kripa Bajaj
Hyderabad

Dr. Krupa Shankar
Coimbatore

Dr. Kshitij Joshi
Mumbai

Dr. Kumar Prabhash
Mumbai

Dr. Manisha Singh
Patna

Dr. Mansi Khanderia
Bengaluru

Dr. Mansi Sharma
Delhi

Dr. Manu Prasad
Kerala

NATIONAL FACULTIES

Dr. Mohit Sharma

Delhi

Dr. Mounika Boppana

Hyderabad

Dr. Mridul Malhotra

Delhi

Dr. Murad Lala

Mumbai

Dr. MV Chandrakanth

Kolkata

Dr. N K Warriar

Calicut

Dr. Nandini Menon

Mumbai

Dr. Naresh Somani

Jaipur

Dr. Narmadha R

Chennai

Dr. Navneet Singh

Chandigarh

Dr. Nikhil Kalyani

Mumbai

Dr. Nikhil Pande

Nagpur

Dr. Nilesh Lokeshwar

Mumbai

Dr. Nitin Chaudhari

Jalgaun

Dr. Nizamudheen M Pareekutty

Kerala

Dr. Omshree Shetty

Mumbai

Dr. P K Das

Delhi

Dr. Pankaj M Shah

Ahmedabad

Dr. Pinaki Mahato

Baroda

Dr. Prabhat Malik

Delhi

Dr. Pradeep Ventrapati

Vizag

Dr. Pradip Mondal

Kolkata

Dr. Prahlad Elamarthi

Mumbai

Dr. Pranav Chaddha

Mumbai

Dr. Prasad Narayanan

Bangalore

Dr. Prasanth Penumadu

Puducherry

Dr. Pratik Chandrani

Mumbai

Dr. Pritam Kalaskar

Mumbai

Dr. Pritam Kataria

Mumbai

Dr. Prriya Eshpuniyani

Mumbai

Dr. Raajit Chanana

Delhi

Dr. Rajat Bajaj

Delhi

Dr. Rajat Saha

Delhi

Dr. Rajeev Saini

Jammu

Dr. Rajesh Mistry

Mumbai

Dr. Rakesh Kapoor

Chandigarh

Dr. Rakesh Pinninti

Hyderabad

Dr. Rakesh Reddy Boya

Vizag

NATIONAL FACULTIES

Dr. Rakesh Taran
Indore

Dr. Ram Abhinav
Coimbatore

Dr. Ramakant Deshpande
Mumbai

Dr. Randeep Singh
Delhi

Dr. Ranga Rao
Delhi

Dr. Ravi Jaiswal
Raipur

Dr. Ravi Thippeswamy
Bangalore

Dr. Ravindra Nandhana
Vizag

Dr. Ritesh T
Silchar

Dr. Rohan Bhise
Belgaum

Dr. Rohit Swami
Jaipur

Dr. Roshni Pande
Jabalpur

Dr. Rushabh Kothari
Ahmedabad

Dr. S H Advani
Mumbai

Dr. S S Alurkar
Ahmedabad

Dr. Sachin Khurana
Delhi

Dr. Sameer Khatri
Delhi

Dr. Sameer Shrirangwar
Nagpur

Dr. Sandeep Ishi
Nasik

Dr. Sandeep Jasuja
Jaipur

Dr. Sanyo Dsouza
Mangalore

Dr. Saravana Rajamanicka
Coimbatore

Dr. Satvik Khaddar
Ahmedabad

Dr. Sewanti Limaye
Mumbai

Dr. Shantanu Pendse
Ahmedabad

Dr. Shekhar Patil
Bengaluru

Dr. Shruti Kate
Nasik

Dr. Shubham Garg
Delhi

Dr. Siddharth Turkar
Raipur

Dr. Somnath Roy
Mumbai

Dr. Sridhar PS
Bangalore

Dr. Sudeep Das
Kolkata

Dr. Sujit Rajan
Mumbai

Dr. Sunil Chopade
Pune

Dr. Sunit Lokwani
Jabalpur

Dr. Sunny Jandyal
Jammu

Dr. Suresh Babu
Bangalore

Dr. Suresh Kumar
Chennai

NATIONAL FACULTIES

Dr. SVSS Prasad

Hyderabad

Dr. Swaratika Majumdar

Bangalore

Dr. Swarnabindu Banerjee

Kolkata

Dr. Syed Nisar

Srinagar

Dr. T P Sahoo

Bhopal

Dr. Tanmoy Kr. Mandal

Kolkata

Dr. Tarachand Gupta

Jaipur

Dr. Tejinder Singh

Mumbai

Dr. Trianjan Basu

Mumbai

Dr. Trupti Pai

Mumbai

Dr. Uma Dangi

Mumbai

Dr. Unnati Desai

Mumbai

Dr. V Kannan

Mumbai

Dr. Vaibhav Choudhary

Nagpur

Dr. Vamshi Krishna

Hyderabad

Dr. Venkatraman Radhakrishnan

Adyar

Dr. Venugopal Arroju

Hyderabad

Dr. Vibhor Sharma

Delhi

Dr. Vijay Patil

Mumbai

Dr. Vijay Sharnangat

Mumbai

Dr. Vikas Talreja

Kanpur

Dr. Vimal Pandita

Dehradun

Dr. Vinayak Makka

Bengaluru

Dr. Vipul Doshi

Solapur

Dr. Virendra Tiwari

Mumbai

Dr. Vivek Agarwala

Kolkata

Dr. Yashwant Kashyap

Raipur

| Time | Topic | Speaker |
|----------------|---|---|
| 01:00-01:55 PM | Lunch | |
| 01:55-02:00 PM | <p>Welcome & Introduction</p> <p>Session Coordinator:</p> <p>Chairpersons:</p> | <p>Dr Vijay Patil, Mumbai</p> <p>Dr Prriya Eshpuniyani, Mumbai</p> <p>Dr Unnati Desai, Mumbai</p> |
| | Session 1: Early Stage 1 | |
| 02:00-02:07 PM | <p>Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial</p> | Dr Prriya Eshpuniyani, Mumbai |
| 02:07-02:14 PM | <p>Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET)</p> | Dr Murad Lala, Mumbai |
| 02:14-02:21 PM | <p>Surgical Outcomes from the Phase 3 Checkmates 816 trial: Nivolumab (NIVO)+ Platinum- doublet Chemotherapy(Chemo) vs chemo alone as neo adjuvant treatmentfor patients with reseactable NSCLC</p> | Dr Arvind Krishnamurthy, Chennai |
| 02:21-02:28 PM | <p>Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery</p> | Dr Kaustav Talapatra, Mumbai |
| 02:28-02:35 PM | <p>Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer</p> | Dr Pratik Chandrani, Mumbai |

02:35-02:42 PM

Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer

**Dr Omshee Shetty,
Mumbai**

02:42-03:10 PM

Panel Discussion

Moderator

**Dr Ramakant Deshpande,
Mumbai**

Panelists

**Dr Saravana R,
Coimbatore
Dr Prasanth Penumadu,
Puducherry
Dr Caleb Harris, Shillong
Dr V Kannan, Mumbai
Dr Virender Tiwari,
Mumbai
Dr Shubham Garg, Delhi
Dr Trupti Pai, Mumbai
Dr Ritesh T, Silchar**

Session Coordinator:

Dr Vipul Doshi, Solapur

Chairpersons:

Dr B K Mishra, Varanasi

Session 2 : Early Stage 2

03:10-03:17 PM

Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial

**Dr Pritam Kataria,
Mumbai**

03:17-03:24 PM

CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer

Dr Hollis Dsouza, Mumbai

03:24-03:31 PM

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC)

**Dr Vijay Sharnangat,
Mumbai**

03:31-03:38 PM

MA08.03 Adjuvant Chemotherapy for Patients with High-Risk Stage I Lung Adenocarcinoma Stratified by Epidermal Growth Factor Receptor Mutation Status

**Dr Uma Dangi,
Mumbai**

03:38-03:45 PM

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy -The Phase 3 PORT-C Randomized Clinical Trial (JAMA ONCOLOGY)

**Dr Trinanjan Basu,
Mumbai**

03:45-04:15 PM

Panel Discussion

Moderator

Dr BK Smruti, Mumbai

Panelists

Dr Rajesh Mistry, Mumbai
**Dr Kripa Bajaj,
Hyderabad**
**Dr Devayani Niyogi,
Mumbai**
Dr Ankita Ahuja, Mumbai
Dr Vipul Doshi, Solapur
**Dr Amita Athawale,
Mumbai**

04:15-05:00 PM

Session Sponsored By:  Roche

Chairperson:
Dr S H Advani, Mumbai

04:15-04:30 PM

Role of Atezolizumab monotherapy in 1L mNSCLC in high PD-L1 patients

Dr Ashish Singh, Vellore

04:30-05:00 PM

Case Based Panel Discussion

Moderator

Dr Minish Jain, Pune

Panelists

Dr Kumar Prabhash, Mumbai
Dr Ashish Joshi, Mumbai
Dr Kaushal Patel, Surat
Dr Amit Joshi, Mumbai
Dr P S Dattatreya, Hyderabad
Dr Raajit Chanana, Delhi

Session Sponsored By:  AstraZeneca

05:00-05:30 PM

Case Based Panel Discussion: Early-Stage Lung Cancer Patient Management- A Multi Disciplinary Team

Moderator

Dr Shyam Aggarwal, Delhi

Panelists

Dr Chakor Vora, Pune
Dr Kaushal Kalra, Delhi
Dr Prriya Eshpuniyani, Mumbai
Dr Robin Thambudorai, Kolkata
Dr Taha Sethjiwala, Indore

05:30-05:40 PM

Tea Break

Session Coordinator:**Dr Sunil Chopade,
Mumbai****Chairpersons:****Dr Pankaj M Shah, Ahmedabad****05:40-05:47 PM**

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

**Dr Rushabh Kothari,
Ahemdabad****05:47-05:54 PM**

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results

**Dr Ram Abhinav,
Coimbatore****05:54-06:01 PM**

LBA44 - Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study

**Dr Arun
Chandrashekhnan,
Calicut****06:01-06:08 PM**

Randomized trial of alectinib plus cetuximab versus alectinib alone for first line treatment of EGFR mutant non small lung cell cancer: Final Results from SWOG S1403


**Dr Nandini Menon,
Mumbai****06:08-06:15 PM**

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm)


Dr Manisha Singh, Patna**06:15-06:22 PM**

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea

**Dr Pinaki Mahato,
Vadodara**

| | | |
|-----------------------|--|---|
| 06:22-06:29 PM | Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients | Dr Shruti Kate, Nashik |
| 06:29-07:00 PM | Panel Discussion | |
| | Moderator | Dr Navneet Singh, Chandigarh |
| | Panelists | Dr Ashish Bakshi, Mumbai Dr Adesh Palekar, Goa Dr Darshana Rane, Mumbai Dr Jayant Gawande, Pune Dr Sunil Chopade, Mumbai Dr Mridul Malhotra, Delhi |
| | Session Coordinator: | Dr Ajay Singh, Mumbai |
| 07:00-07:50 PM | Session Sponsored By:  NOVARTIS Reimagining Medicine | |
| 07:00-07:10 PM | Role of NGS in CMET Detection | Dr Anuradha Choughule, Mumbai |
| 07:10-07:20 PM | Unlocking the unMET Need in met Ex14 M NSCLC | Dr Ullas Batra, Delhi |
| 07:20-07:35 PM | CASE 1- My Early Experience with CMET | Dr Nirmal Raut, Mumbai |
| 07:35-07:50 PM | CASE 2- Met in the Clinic | Dr Sewanti Limaye, Mumbai |

Miscellaneous

| | | |
|-------------------------|---|---|
| 08:00-08:07 PM | Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial | Dr Prahlad E, Mumbai |
| 08:07-08:14 PM | Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs | Dr Sachin Khurana, Delhi |
| 08:14-08:21 PM | Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights | Dr Ajay Singh, Mumbai |
| 08.21-08.45 PM | Session Sponsored-  | |
| 08:21-08:45 PM | Panel Discussion: Choosing Right VAD in Lung Cancer Patients | |
| | Moderator | Dr Ullas Batra, Delhi |
| | Panelists | Dr Minish Jain, Pune Dr Rahul Sud, Bangalore |
| 08.45-08.55 PM | Quiz | Dr Ajay Singh, Mumbai |
| 08.55 PM | Closing Remarks & Followed By Dinner | Dr Vijay Patil, Mumbai |
| 08:55 PM Onwards | CRSF GBM Followed by EC Meeting | |

| Time | Topic | Speaker |
|-----------------------|---|--|
| | Session Coordinator: | Dr. Bharat Bhosale, Mumbai |
| 09:00 AM | Welcome & Introduction | Dr. Bharat Bhosale, Mumbai |
| | Chairpersons: Dr. D Raghunath Rao, Vizag Dr. Roshni Pande, Jabalpur | |
| | Session 1: SCLC | |
| 09:00-09:07 AM | Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung | Dr. Mansi Sharma, Delhi |
| 09:07-09:14 AM | Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538. | Dr. Kinjal Jani, Ahmedabad |
| 09:14-09:21 AM | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial | Dr. Mounika Boppana, Hyderabad |
| 09:21-09:28 AM | Nivolumab and Ipilimumab as maintenance therapy in extensive - disease small- cell- lung cancer : Checkmate 451 | Dr. Swaratika Majumdar, Bangalore |
| 09:28-09:35 AM | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) | Dr. Ghanshyam Biswas, Bhubneshwar |

09:35-09:42 AM

MA16.02 Platinum-Doublets as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Dr. Arvind Kumar, Patna

09:42-09:49 AM

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy

Dr. Itesh Khatwani, Ahmedabad

Session Sponsored By: **AstraZeneca** 

09:50-10:20 AM

Case Based Panel Discussion: Ideal Management of 1L ES- SCLC

Moderator:

Dr Sajjan Rajpurohit, Delhi

Panelists:

Dr. Rakesh Reddy Boya, Vizag
Dr. C.T. Satheesh, Bangalore
Dr. Lakhan Kashyap, Varanasi

10:20-10:30 AM

Tea Break

Session Coordinator:

Dr. Sunil Chopade, Mumbai

Session 2: Post Progression EGFR

10:30-10:37 AM

ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Dr. Sunit Lokwani, Jabalpur

10:37-10:44 AM

Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer

Dr. Satvik Khaddar, Ahmedabad

| Time | Topic | Speaker |
|----------------|--|---|
| 10:44-10:51 AM | Olmotinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | Dr. Vaibhav Choudhary, Nagpur |
| 10:51-10:58 AM | Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). | Dr. Rajat Bajaj, Delhi |
| 10:58-11:05 AM | MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib | Dr. Rakesh Pinninti, Hyderabad |
| 11:05-11:12 AM | MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers | Dr. Rajat Saha, Delhi |
| 11:12-11:19 AM | 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study | Dr. Dilip Harindran Vallathol, Visakhapatnam |
| 11:19-11:26 AM | Mechansims of Post EGFR resistance & Options of therapy | Dr. Vivek Agarwala, Kolkata |
| | Session Coordinator: | Dr. Ajay Singh, Mumbai |
| | Chairpersons: Dr. Manisha Singh, Patna | |
| | Session 3: ALK | |
| 11:26-11:33 AM | First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | Dr. Chakor Vora, Pune |
| 11:33-11:40 AM | Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. | Dr. Manu Prasad, Kerala |
| 11:40-11:47 AM | Assessment of alectinib vs ceritinib in ALK-positive non-small cell lung cancer in phase 2 trials and in real-world data | Dr. Suresh Babu, Bangalore |

11:47-11:54 AM

Final OS analysis from the phase III j-alex study of alectinib (ALLC) versus crizotinib (CRZ) in Japanese ALK-Inhibitors naive ALK positive non m=small cell lung cancer(ALK + NSCLC)

**Dr. Pritam Kalaskar,
Mumbai**

11:54 AM-12:00 PM

Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer

**Dr. Bhavesh Poladia,
Namakkal**

12:00-12:30 PM

Panel Discussion

Moderator:

**Dr. Vamshi Krishna,
Hyderabad**

Panelists:

**Dr. Tarachand Gupta,
Jaipur
Dr. Vibhor Sharma, Delhi
Dr. Sunny Jandiyal,
Jammu
Dr. Nitin Chaudhari,
Jalgaun**

Session Sponsored By:  **GUARDANT™**

12.30-12.40 PM

The Economic VALUE of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer

**Dr. Vanita Noronha,
Mumbai**

Session Coordinator:

**Dr. Shantanu Pendse,
Mumbai**

Chairpersons:

Dr. Jacob George, Goa

Session 4: Post ALK

12:40-12:47 PM

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

**Dr. Pradip Mondal,
Kolkata**

12:47-12:54 PM

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing

Dr. Sudeep Das, Kolkata

| Time | Topic | Speaker |
|----------------|---|---|
| 12:54-01:01 PM | BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer | Dr. Nikhil Pande, Nagpur |
| 01:01-01:08 PM | Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer | Dr. Amit Aggarwal, Raipur |
| 01:08-01:15 PM | Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation | Dr. Chetan Deshmukh, Pune |
| 01:15-01:22 PM | Abstract 5226: TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors | Dr. Sameer Shrirangwar, Nagpur |
| 01:22-01:55 PM | Panel Discussion Moderator: Panelists: | Dr T P Sahoo, Bhopal Dr. Kshitij Joshi, Mumbai Dr. Shekhar Patil, Bangalore Dr. Kaushal Patel, Surat Dr. Sameer Khatri, Delhi Dr. Bharath Rangarajan, Coimbatore |
| 01:55-02:40 PM | Lunch Break Session Coordinator: Chairpersons: Dr. S S Alurkar, Ahmedabad Dr. K Sambasivaiah, Varanasi | Dr. Anne Srikanth, Mumbai |
| | Session 5 : ROS & HER2 | |
| 02:40-02:47 PM | Updated Integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion - positive non-small-cell lung cancer | Dr. Ravi Jaiswal, Raipur |
| 02:47-02:54 PM | Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer | Dr. Anjana Joel, Vellore |

| Time | Topic | Speaker |
|----------------|--|---|
| 02:54-03:01 PM | Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial. Add to Collection | Dr. Prabhat Malik, Delhi |
| 03:01-03:08 PM | MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial | Dr. Novak Gupta, Delhi |
| 03:08-03:15 PM | Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry | Dr. Gunjesh Kumar Singh, Muzaffarpur, Bihar |
| 03:15-03:22 PM | Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series | Dr. Shashank Das, Kharghar |
| 03:22-04:00 PM | <p>Panel Discussion</p> <p>Moderator:</p> <p>Panelists:</p> <p>Moderator:</p> | <p>Dr. Randeep Singh, Delhi</p> <p>Dr. Vinayak V Makka, Bangalore Dr. Mohit Sharma, Delhi Dr. Vimal Pandita, Dehradun Dr. Rajeev Saini, Jammu Dr. Bipinesh Sansar, Varanasi</p> <p>Dr. Ramakant Deshpande, Mumbai Dr. V. Kannan, Mumbai Dr. S D Banavali, Mumbai Dr. Rajesh Mistry, Mumbai Dr. Kumar Prabhash, Mumbai</p> |
| 04:00-04:30 PM | CRSF Oration | Padma Shri Dr. R Ravi Kannan, Assam |

Session Coordinator:

**Dr. Goutam Panda,
Mumbai**

Chairperson:

Dr. K. Pavithran, Kochi

MET

04:30-04:37 PM

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

Dr. Amol Dongre, Nagpur

04:37-04:44 PM

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).

**Dr. Aditya Kanteti,
Mumbai**

04:44-04:51 PM

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

**Dr. Avinash Talele,
Mumbai**

04:51-04:58 PM

OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer.

**Dr. Tanmoy Kr
Mandal, Kolkata**

04:58-05:05 PM

Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: the GeoMETry-III phase 3 study

**Dr. Siddharth Turkar,
Raipur**

05:05-05:12 PM

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Dr. Akhil Kapoor, Varanasi

05:12-05:40 PM

Panel Discussion

Moderator:

**Dr. Venkatraman
Radhakrishnan, Adyar**

Panelists:

**Dr. Naresh Somani, Jaipur
Dr. Ravi Thippeswamy,
Bangalore
Dr. G. Sadashivudu,
Hyderabad
Dr. Venugopal Arroju,
Hyderabad
Dr. Adwaita Gore,
Mumbai**

05:40-06:00 PM

Tea Break

| | | |
|----------------|--|--|
| 06:00-06:45 PM | Session Sponsored By:  | |
| 06:00-06:05 PM | EGFRm+ advanced NSCLC Treatment Landscape | Dr. Kumar Prabhash, Mumbai |
| 06:05-06:15 PM | RELAYing RELAY | Dr. B K Smruti, Mumbai |
| 06:15-06:40 PM | Clinical case based discussion: Does One size fit all – What information will help improve our treatment decisions in advanced EGFRm+ NSCLC? | |
| | Moderator: | Dr. Sewanti Limaye, Mumbai |
| | Panelists: | Dr. Ashish Singh, Vellore Dr. Krupa Shankar, Coimbatore |
| 06:40-06:45 PM | Summary & Closure | Dr. Kumar Prabhash, Mumbai |
| 06:45-07:25 PM | Session Sponsored By:  | |
| 06.45-07.05 PM | Dissecting molecular differences between Exon 19 and Exon 21 mutations | Dr. Amit Joshi, Mumbai |
| 07.05-07.25 PM | Addressing unmet needs in the ALK treatment landscape | Dr Kaushal Patel, Surat |
| | Session Coordinator: | Dr. Mridul Malhotra, Gurugram |
| | Chairpersons: Dr. Hemant Malhotra, Jaipur Dr. Govind Babu, Bangalore | |

EGFR EXON 20 Insertions

| | | |
|-------------------------|---|---------------------------------------|
| 07:30-07:37 PM | Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions | Dr. Somnath Roy, Mumbai |
| 07:37-07:44 PM | OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy | Dr. Shantanu Pendse, Ahmedabad |
| 07:44-07:51 PM | Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study | Dr. Kishore Kota, Varanasi |
| 07:51-07:58 PM | Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | Dr. Raajit Chanana, Delhi |
| 07:58-08:05 PM | Pozitotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program | Dr. Aditya Murali, Bangalore |
| | Session Sponsored By: Pfizer Vaccine | |
| 08:05-08:35 PM | Vaccination of Oncology Patients - An effective tool & an opportunity not to be missed | Dr. T P Sahoo, Bhopal |
| | Session Sponsored By:  4baseCare Together, We Beat Cancer | |
| 08:35-08:50 PM | Mutational landscape in Indian non-small cell lung cancer patients using a whole-exome sequencing approach | Dr. Vidya Veldore, Bangalore |
| 08.50 PM Onwards | Closing Remarks & Followed By Dinner | Dr Vijay Patil, Mumbai |

| Time | Topic | Speaker |
|----------------|---|---|
| 09.00 AM | <p>Welcome & Introduction</p> <p>Session Coordinator:</p> <p>Chairpersons: Dr Rakesh Taran, Indore Dr V Kannan, Mumbai</p> <p>Session 1: Stage 3 NSCLC</p> | <p>Dr Ashay Karpe, Mumbai</p> <p>Dr Nandini Menon, Mumbai</p> |
| 09:00-09:07 AM | <p>Skinner, H., et al. (2021) Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial. JAMA Oncology</p> | <p>Dr. Nikhil Kalyani, Mumbai</p> |
| 09:07-09:14 AM | <p>Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L</p> | <p>Dr Pranav Chaddha, Mumbai</p> |
| 09.14-09.21 AM | <p>Phase 3 study of pembrolizumab with cocurent chemoradiation therapy followed by pembrolizumab with or wiithout olaparib versus concurrent chemoradiation theraphyfollowed by durvalumab in unresctable , locally advanced, stage III non small cell lung cancer :KEYLYNK 012</p> | <p>Dr. Nilesh Lokeshwar, Mumbai</p> |
| 09.21-09.28 AM | <p>1171MO - PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy</p> | <p>Dr Peush Bajpai, Delhi</p> |

Session Sponsored By: **AstraZeneca** 

09.30-09.55 AM

Case Based Panel Discussion: Optimal Management of Stage III NSCLC

Moderator:

Dr Sushant Mittal, Delhi

Panelists:

Dr. Ramakant Deshpande, Mumbai
Dr PK Das, Delhi
Dr. Anil Tibdewal, Mumbai
Dr. Sridhar PS, Bangalore
Dr. Ashish Joshi, Mumbai
Dr Gagan Saini, Delhi

Session Coordinator:

Dr Anu Rajpurohit, Jaipur

Chairpersons:

Dr N K Warriar, Callicut

Session 2: Neoadjuvant Immunotherapy

09.55-10.02 AM

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)

Dr. Boman Dhabhar, Mumbai

10.02-10.09 AM

Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer

Dr. Rohit Swami, Jaipur

10.09-10.16 AM

OA20.01 Long Term Survival in Operable Stage Iiiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

Dr Narmadha R, Chennai

10.16-10.23 AM

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Dr. Prasad Narayanan, Bangalore

10.23-10.30 AM

OA20.05 Neoadjuvant Chemotherapy-alone vs Chemoradiation followed by Sleeve Resection for Locally Advanced Non-Small Cell Lung Cancer

Dr. Pradeep Ventrapati, Vizag

10.30-11.00 AM

Panel Discussion

Moderator:

Dr. Chirag Desai,
Ahmedabad

Panelists:

Dr. Anuj Gupta, Varanasi
Dr. Nizamudheen M
Pareekutty, Kerala
Dr. Yashwant Kashyap,
Raipur
Dr. Hollis Dsouza, Mumbai
Dr Ashay Karpe, Mumbai

Session Coordinator:

Dr Akhil Kapoor, Varanasi

Chairpersons:

Dr Jatin Sarin, Chandigarh
Dr Sandeep Jasuja, Jaipur**Session 3: 1st Line Immunotherapy**

11:00-11:07 AM

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA

Dr Krupa Shankar,
Coimbatore

11:07-11:14 AM

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis

Dr MV Chandrakanth,
Kolkata

11:14-11:21 AM

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227

Dr. Sanyo Dsouza,
Mangalore

11:21-11:28 AM

Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to first-line immunotherapy vs chemotherapy in patients with mNSCLC: analyses from the Phase 3 MYSTIC trial

Dr. Ravindra Nandhana,
Vizag

| Time | Topic | Speaker |
|-------------------|---|--------------------------------------|
| 11:28-11:35 AM | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (Impower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial | Dr Vikas Talreja, Kanpur |
| 11:35-11:42 AM | Five year outcomes with pembrolizumab versus chemotherapy for metastatic non-small- lung cancer with Pd- L1 Tumor Proportion score -> 50% | Dr. Deepak Shukla, Jaipur |
| 11:42-11:49 AM | Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score > 50% : Randomized double blinded phase III ketnote | Dr. Abhinav Zawar, Aurangabad |
| 11:49-11:56 AM | LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) | Dr. Ashay Karpe, Mumbai |
| | <p>Session Coordinator:</p> <p>Chairpersons: Dr. Devendra Pal, Mumbai Dr S H Advani, Mumbai</p> <p>Tips for Immunotherapy</p> | Dr Hollis Dsouza, Mumbai |
| 11:56 AM-12:03 PM | Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database | Dr. Anu Rajpurohit, Jaipur |
| 12:03-12:10 PM | Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study. | Dr. Davinder Paul, Ludhiana |
| 12:10-12:17 PM | Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors | Dr. Gurvinder Singh, Sangrur |

Time

Topic

Speaker

12:17-12:24 PM

Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials Impower130, IMpower132, and Impower150.

**Dr. Suresh Kumar,
Chennai**

Session Sponsored By:  Bristol Myers Squibb

12:30-12:50 PM

“Long term survival outcomes with Nivolumab in mNSCLC”

Dr Vijay Patil, Mumbai

12:50-01:20 PM

Session Sponsored By:  **MSD**
INVENTING FOR LIFE

Redefining Survival Expectations in NSCLC(Keynote-189 & Keynote-407)

**Dr MV Chandrakanth,
Kolkata**

01:20-01:30 PM

Mega Quiz

Dr Vikas Talreja, Kanpur

01:30 PM Onwards

Followed By Lunch

SCIENTIFIC PARTNERS



Inj. Topotecan 2.5 mg



CONFERENCE VENUE



Sahara Star Hotel, Mumbai

**Nehru Rd, opp. Domestic Airport, Navpada, Vile Parle East,
Vile Parle, Mumbai, Maharashtra 400099**

CONTACT US :
GARIMA VASISTH : +91 8178985238



Digital Conference Managed By:
**Horizon Conference
Management Pvt. Ltd.**